Critical Survey: Predictive Oncology (NASDAQ:AGPU) versus ReShape Lifesciences (OTCMKTS:RSLSD)

ReShape Lifesciences (OTCMKTS:RSLSD) and Predictive Oncology (NASDAQ:AGPU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Risk & Volatility

ReShape Lifesciences has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500. Comparatively, Predictive Oncology has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Valuation & Earnings

This table compares ReShape Lifesciences and Predictive Oncology”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$610,000.00	0.00	-$81.15 million	N/A	N/A
Predictive Oncology	$1.62 million	4.23	-$12.66 million	($13.50)	-0.15

Predictive Oncology has higher revenue and earnings than ReShape Lifesciences.

Analyst Ratings

This is a breakdown of current recommendations and price targets for ReShape Lifesciences and Predictive Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	0	0	0.00
Predictive Oncology	1	0	0	0	1.00

Given ReShape Lifesciences’ higher possible upside, equities analysts plainly believe ReShape Lifesciences is more favorable than Predictive Oncology.

Institutional & Insider Ownership

9.0% of Predictive Oncology shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares ReShape Lifesciences and Predictive Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-668.58%	-163.22%	-52.10%
Predictive Oncology	-5,065.23%	N/A	-235.55%

Summary

Predictive Oncology beats ReShape Lifesciences on 6 of the 10 factors compared between the two stocks.

About ReShape Lifesciences

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.

About Predictive Oncology

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.